FrancophonIA/ELRC3.0 huggingface dataset:
English: There is no target-based cross-resistance between imipenem and agents of the quinolone, aminoglycoside, macrolide and tetracycline classes.
Estonian: Kinoloonide, aminoglükosiidide, makroliidide ja tetratsükliinide rühmade esindajaid sisaldavate ravimite ja imipeneemi suhtes ei ole ristresistentsust.
English: It is important that you tell your doctor if you are pregnant or are planning to become pregnant before receiving TIENAM.
Estonian: Enne TIENAMi võtma hakkamist peate rääkima arstile oma rasedusest või kavatsusest rasedaks jääda.
English: The concomitant use of imipenem/cilastatin and valproic acid/sodium valproate is not recommended (see section 4.5).
Estonian: Imipeneemi/tsilastatiini ei soovitata kasutatada samal ajal koos valproehappe/naatriumvalproaadiga (vt lõik 4.5).
English: The antibacterial spectrum of imipenem/cilastatin should be taken into account especially in lifethreatening conditions before embarking on any empiric treatment.
Estonian: Eeskätt eluohtlike seisundite korral peab enne empiirilise ravi alustamist võtma arvesse imipeneemi/tsilastatiini antibakteriaalset spektrit.
English: • very common: affects more than 1 user in 10
Estonian: • Väga sage: esineb rohkem kui 1 kasutajal 10-st
English: Distribution The binding of cilastatin to human serum proteins is approximately 40%.
Estonian: Jaotumine Inimese plasmavalkudega seondub ligikaudu 40% tsilastatiinist.
English: • Irregular heartbeat, the heart beating forcefully or rapidly
Estonian: • Ebakorrapärased südamelöögid, liiga tugevad või kiired südamelöögid
English: At the higher dose, the exposure following administration of 25/25 mg/kg imipenem/cilastatin to children was 9% higher as compared to the exposure in adults receiving a 1000 mg/1000 mg dose.
Estonian: Kui lastele manustati suurem annus imipeneemi/tsilastatiini, 25 mg/25 mg/kg, oli laste ekspositsioon 9% kõrgem kui 1000 mg/1000 mg annuse saanud täiskasvanutel.
English: If these side-effects occur while receiving or after receiving TIENAM, the medicine must be stopped and your doctor contacted immediately.
Estonian: TIENAMi manustamist need kõrvaltoimed, siis tuleb ravimi manustamine kohe lõpetada ja võtta ühendust arstiga.
English: The usual dose for children one year of age or older is 15/15 or 25/25 mg/kg/dose every 6 hours.
Estonian: Üheaastastel ja vanematel lastel on TIENAMi harilik annus 15/15 või 25/25 mg/kg iga 6 tunni tagant.
English: Elderly population No dose adjustment is required for the elderly patients with normal renal function (see section 5.2).
Estonian: Eakad patsiendid Normaalse neerutalitlusega eakatel patsientidel pole annuse kohaldamine vajalik (vt lõik 5.2).
English: Haematology A positive direct or indirect Coombs test may develop during treatment with imipenem/cilastatin.
Estonian: Imipeneemi/tsilastatiiniga ravimise ajal võib kujuneda positiivne vastus otsesele või kaudsele Coombsi testile.
English: Spain: TIENAM IV
Estonian: Hispaania: TIENAM IV
English: The AUC for imipenem following administration of 15/15 mg/kg per body weight of imipenem/cilastatin to paediatric patients was approximately 30% higher than the exposure in adults receiving a 500 mg/500 mg dose.
Estonian: Lastel oli pärast 15 mg/15 mg imipneemi/tsilastatiini manustamist kehakaalu kilogrammi kohta imipeneemi kõveraalune pindala ligikaudu 30% suurem kui täiskasvanutel, kes said 500 mg/500 mg-se annuse.
English: Due to the limited extent of hepatic metabolism of imipenem, its pharmacokinetics are not expected to be affected by hepatic impairment.
Estonian: Et imipeneemi metaboliseeritakse maksas vähesel määral, ei arvata maksapuudulikkuse mõju farmakokineetikale.
English: Rare staining of teeth and/or tongue
Estonian: Harv keele ja/või hammaste värvuse muutus
English: • Inflammation of stomach or intestine (gastro-enteritis)
Estonian: • Mao või soolestiku põletik (gastroenteriit)
English: • very rare: affects less than 1 user in 10,000
Estonian: • Väga harv: esineb vähem kui 1 kasutajal 10 000-st:
English: Uncommon pancytopenia, neutropenia, leucopenia, thrombocytopenia, thrombocytosis
Estonian: Aeg-ajalt pantsütopeenia, neutropeenia,leukopeenia, trombotsütopeenia, trombotsütoos
English: For paediatric patients ≥1 year of age, the recommended dose is 15/15 or 25/25 mg/kg/dose administered every 6 hours.
Estonian: Lapsed ≥ 1 aasta vanuses Lastele vanuses ≥ 1 aastat on soovitatav annus 15/15 või 25/25 mg/kg manustatuna iga 6 tunni tagant.
English: Paediatric (≥3 months of age)
Estonian: Lapsed (3-kuused või vanemad)
English: • Severe skin rash with loss of skin and hair (exfoliative dermatitis)
Estonian: • Raske nahalööve kestendamise ja karvade väljalangemisega (eksfoliatiivne dermatiit)
English: Do not freeze the reconstituted solution.
Estonian: Ärge hoidke valmistatud lahust sügavkülmas.
English: Romania: TIENAM IV
Estonian: Rumeenia: TIENAM IV
English: TIENAM is not recommended in children under one year of age and children with kidney problems.
Estonian: TIENAMi ei soovitata kasutada noorematel kui 1-aastastel lastel ja neeruprobleemidega lastel.
English: Central nervous system
Estonian: Kesknärvisüsteem
English: Uncommon seizures, myoclonic activity, dizziness, somnolence
Estonian: Aeg-ajalt krambid, müokloonne aktiivsus, pearinglus, somnolentsus
English: Hence close adherence to recommended dose schedules is urged especially in these patients (see section 4.2).
Estonian: Seetõttu rõhutatakse just selliste patsientide puhul vajadust soovitatud annustamisskeeme hoolikalt järgida (vt lõik 4.2).
English: The urinary recovery of active (non-metabolized) imipenem decreased to approximately 60% of the dose when TIENAM was administered with probenecid.
Estonian: Kui TIENAMi manustati koos probenetsiidiga, vähenes aktiivse (mittemetaboliseeritud) imipeneemi eritumine uriiniga ligikaudu 60%-ni annusest.
English: • Imipenem is stable to hydrolysis by most beta-lactamases, including penicillinases and cephalosporinases produced by gram-positive and gram-negative bacteria, with the exception of relatively rare carbapenem hydrolysing beta-lactamases.
Estonian: • Imipeneen ei hüdrolüüsu enamike β-laktamaaside toimel, sealhulgas grampositiivsete ja gramnegatiivsete bakterite poolt toodetavate penitsillinaaside ja tsefalosporinaaside toimel.
English: Rare encephalopathy, paraesthesia, focal tremor, taste perversion
Estonian: Harv entsefalopaatia, paresteesia, fokaalne treemor, maitsmishäired
English: United Kingdom: Primaxin IV
Estonian: Ühendkuningriik: Primaxin IV
English: Each vial contains sodium bicarbonate equivalent to approximately 1.6 mEq of sodium (approximately 37.6 mg).
Estonian: Igas viaalis on 1,6 mEq naatriumile (ligikaudu 37,6 mg) vastav kogus naatriumbikarbonaati.
English: Very rare gastro-enteritis
Estonian: Väga harv gastroenteriit
English: In healthy elderly volunteers (65 to 75 years of age with normal renal function for their age), the pharmacokinetics of a single dose of TIENAM 500 mg/500 mg administered intravenously over 20 minutes were consistent with those expected in subjects with slight renal impairment for which no dose alteration is considered necessary.
Estonian: 20 minuti jooksul intravenoosselt manustatud TIENAMi 500 mg / 500 mg üksikannuse farmakokineetika oli eakatel tervetel uuritavatel (vanuses 65...75 aastat ja oma ea kohta normaalse neerutalitlusega) kooskõlas kerge, annuse kohaldamist mittenõudva neerupuudulikkusega patsientide puhul oodatavaga.
English: The average clearance (CL) and volume of distribution (Vdss) for imipenem were approximately 45% higher in paediatric patients (3 months to 14 years) as compared to adults.
Estonian: Lastel (vanuses 3 kuud kuni 14 aastat) olid imipeneemi keskmine kliirens ja jaotusruumala ligikaudu 45% kõrgemad kui täiskasvanutel.
English: • Infection affecting the lungs (pneumonia)
Estonian: • Kopse haarav infektsioon (kopsupõletik)
English: Do not store above 25 C.
Estonian: Hoida temperatuuril kuni 25 °C
English: Antibiotic-associated colitis and pseudomembranous colitis have been reported with imipenem/cilastatin and with nearly all other anti-bacterial agents and may range from mild to life-threatening in severity.
Estonian: Imipeneemi/tsilastatiiniga ja peaaegu kõikide teiste antibakteriaalsete ravimite puhul on kirjeldatud antibiootikumidega kaasnevat koliiti ja pseudomembranoosset koliiti, mille raskusaste võib ulatuda kergest kuni eluohtlikuni.
English: Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.
Estonian: Ükskõik millise ülal loetletud infektsiooniga seonduva või arvatavasti seonduva baktereemiaga patsientide ravi.
English: Hepatic
Estonian: Hematoloogia
English: Concomitant use of an appropriate anti-MRSA agent may be indicated when MRSA infections are suspected or proven to be involved in the approved indications.
Estonian: Kui ülaltoodud näidustuste juures kahtlustatakse või leiab kinnitust MRSA-infektsioon, on näidustatud samaaegne ravi MRSA-vastaste ravimitega.
English: The mean peak plasma levels of imipenem following the 250 mg/250 mg, 500 mg/500 mg, and 1000 mg /1000 mg doses were 17, 39, and 66 μg/ml, respectively.
Estonian: Pärast 250 mg / 250 mg, 500 mg / 500 mg ja 1000 mg / 1000 mg annuseid olid keskmised maksimumkontsentratsioonid plasmas vastavalt 17, 39 ja 66 μg/ml.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each vial contains: imipenem 500 mg and cilastatin 500 mg.
Estonian: TOIMEAINE(TE) SISALDUS Igas viaalis on: 500 mg imipeneemi ja 500 mg tsilastatiini.
English: Iceland: Tienam
Estonian: Island: Tienam
English: PHARMACEUTICAL FORM AND CONTENTS Powder for solution for infusion
Estonian: RAVIMVORM JA PAKENDI SUURUS Infusioonilahuse pulber
English: Anticonvulsant therapy should be continued in patients with a known seizure disorder.
Estonian: Teadaoleva krambihäirega patsientidel tuleb jätkata krambivastast ravi.
English: Ireland: Primaxin IV
Estonian: Iirimaa: Primaxin IV
English: Increases in serum transaminases and in alkaline phosphatase are also commonly reported.
Estonian: Sageli kirjeldatakse ka seerumi transaminaaside ja aluselise fosfataasi sisalduse suurenemist.
English: Very rare vertigo, tinnitus
Estonian: Väga harv peapööritus, tinnitus
English: Imipenem/Cilastatin
Estonian: Imipeneem/tsilastatiin
English: Patients on haemodialysis
Estonian: Hemodialüüsitavad patsiendid
English: Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant.
Estonian: Isolaate tuleb kirjeldada resistentsetena seni, kuni puuduvad tõendid kliinilisest ravivastusest, mis on leidnud kinnitust isolaatidel, mille MIK-väärtus on üle praeguse resistentsuse läviväärtuse.
English: TIENAM is given intravenously (into a vein) over 20-30 minutes for a dose of ≤500 mg/500 mg or 40-60 minutes for a does of >500 mg/500 mg.
Estonian: TIENAMi manustatakse intravenosselt (veeni) ≤500 mg/500 mg annust 20...30 minuti jooksul ja >500 mg/500 mg annust 40...60 minuti jooksul.
English: Imipenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).
Estonian: Imipeneem toimib bakteritsiidselt, seondudes penitsilliini siduvate valkudega (ingl penicillin-binding proteins, PBPs) ning pärssides niiviisi grampositiivsete ja gramnegatiivsete bakterite rakuseinte sünteesi.
English: • Hearing loss
Estonian: • Kuulmislangus
English: Approximately 70-80% of the dose of cilastatin was recovered unchanged in the urine as cilastatin within 10 hours of administration of TIENAM.
Estonian: 10 tunni jooksul pärast TIENAMi manustamist eritub ligikaudu 70...80% tsilastatiini annusest muutumatult kujul uriiniga.
English: Therefore, no dose adjustment is recommended in patients with hepatic impairment (see section 4.2).
Estonian: Seetõttu ei soovitata maksapuudulikkusega patsientidel annuseid muuta (vt lõik 4.2).
English: * A further proportionate reduction in dose administered must be made for patients with a body weight
Estonian: * < 70 kg kehakaaluga patsientide annust tuleb proportsionaalselt veelgi vähendada.
English: • Complicated skin and soft tissue infections
Estonian: • Naha ja pehmete kudede komplitseeritud infektsioonid
English: This medicinal product must not be mixed with other medicinal products except those mentioned under Reconstitution.
Estonian: Seda ravimpreparaati tohib kokku segada ainult lõigus Lahustamine mainitud ravimpreparaatidega.
English: • Disease of the brain, tingling sensation (pins and needles), localised tremor
Estonian: • Ajuhaigused, kihelustunne (torkimistunne), lokaalne treemor
English: - The other ingredient is sodium bicarbonate.
Estonian: Abiaine on naatriumbikarbonaat.
English: Very rare dyspnoea, hyperventilation, pharyngeal pain
Estonian: Väga harv düspnoe, hüperventilatsioon, kurguvalu
English: Medicinal products that inhibit peristalsis should not be given.
Estonian: Ei tohi kasutada peristaltikat pärssivaid ravimpreparaate.
English: • Local skin redness
Estonian: • Naha paikne punetus
English: In normal volunteers, intravenous infusion of TIENAM over 20 minutes resulted in peak plasma levels of imipenem ranging from 12 to 20 μg/ml for the 250 mg/250 mg dose, from 21 to 58 μg/ml for the 500 mg/500 mg dose, and from 41 to 83 μg/ml for the 1000 mg/1000 mg dose.
Estonian: TIENAMi manustamisel tervetele vabatahtlikele 20 minuti jooksul intravenoosse infusioonina, tõusid imipeneemi maksimaalsed plasmakontsentratsioonid 12...20 μg/ml 250 mg / 250 mg annuse puhul; 21...58 μg/ml 500 mg / 500 mg annuse puhul ning 41...83 μg/ml 1000 mg / 1000 mg annuse puhul.
English: • Worsening of a rare disease associated with muscle weakness (aggravation of myasthenia gravis)
Estonian: • Haruldase haigusega kaasneva lihasnõrkuse süvenemine (müasteenia ägenemine)
English: Luxembourg: Tienam
Estonian: Luksemburg: Tienam
English: The mean peak plasma levels of cilastatin following the 250 mg/250 mg, 500 mg/500 mg, and 1000 mg/1000 mg doses were 22, 42, and 72 µg/ml respectively.
Estonian: Pärast 250 mg / 250 mg, 500 mg / 500 mg ja 1000 mg / 1000 mg annuseid olid tsilastatiini keskmised maksimumkontsentratsioonid plasmas vastavalt 22, 42 ja 72 μg/ml.
English: TIENAM may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
Estonian: • naha ja pehmete kudede komplitseeritud infektsioonid TIENAMi võib kasutada neutropeeniaga patsientide ravis, kellel on arvatavalt bakteriaalsest infektsioonist tingitud palavik.
English: Animal studies showed that the toxicity produced by imipenem, as a single entity, was limited to the kidney.
Estonian: Loomkatsed näitasid, et omaette manustamisel piirdub imipeneemi toksiline mõju neerudega.
English: Common eosinophilia
Estonian: Sage eosinofiilia
English: • Enterobacteriaceae 1: S ≤2 mg/l, R >8 mg/l
Estonian: • Enterobacteriaceae 1: T ≤ 2 mg/l, R > 8 mg/l
English: Patients with creatinine clearances of 5 ml/min/1.73 m2 should not receive TIENAM unless haemodialysis is instituted within 48 hours.
Estonian: Patsientidele kreatiniini kliirensiga  5 ml/min /1,73 m2 tohib TIENAMi manustada ainult siis, kui 48
English: • Local pain and formation of a firm lump at the injection site
Estonian: • Paikne valu ja kõva muhu teke süstekohal
English: PHARMACEUTICAL FORM Powder for solution for infusion.
Estonian: Pulber infusioonilahuse valmistamiseks.
English: Netherlands: TIENAM I.V.
Estonian: Holland: TIENAM I.V.
English: France: TIENAM
Estonian: Prantsusmaa: TIENAM
English: The pharmacokinetics of imipenem in patients with hepatic insufficiency have not been established.
Estonian: Maksapuudulikkusega patsientidel pole imipeneemi farmakokineetikat välja selgitatud.
English: Estonia: TIENAM I.V.
Estonian: Eesti: TIENAM I.V.
English: Sweden: Tienam
Estonian: Rootsi: Tienam
English: What TIENAM looks like and contents of the pack TIENAM is a white to light yellow powder for solution for infusion in a glass vial.
Estonian: TIENAM on klaasviaalis olev valget kuni helekollast värvi pulber infusioonilahuse valmistamiseks.
English: Decreases in valproic acid levels that may fall below the therapeutic range have been reported when valproic acid was co-administered with carbapenem agents.
Estonian: Valproehappe manustamisel koos karbapeneemantibiootikumidega on kirjeldatud valproehappe kontsentratsioonide vähenemist, mis võib langeda allapoole terapeutilist vahemikku.
English: Urinary recovery, renal clearance and plasma clearance of imipenem and cilastatin decrease with decreasing renal function following intravenous administration of TIENAM.
Estonian: Pärast TIENAMi intravenoosset manustamist kahaneb imipeneemi ja tsilastatiini uriiniga väljutamine, neerukliirens ning plasmakliirens koos neerutalitluse kahanemisega.
English: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams.
Estonian: Ülitundlikkus β-laktaamidega ravitavatel patsientidel on kirjeldatud raskeid ja mõnikord surmaga lõppenud ülitundlikkusreaktsioone (anafülaktilised reaktsioonid).
English: Hungary: Tienam
Estonian: Ungari: Tienam
English: Peak plasma levels of cilastatin, following a 20 minute intravenous infusion of TIENAM, ranged from 21 to 26 μg/ml for the 250 mg/250 mg dose, from 21 to 55 μg/ml for the 500 mg/500 mg dose and from 56 to 88 μg/ml for the 1000 mg/1000 mg dose.
Estonian: TIENAMi manustamisel intravenoosse infusioonina 20 minuti jooksul olid tsilastatiini maksimaalsed plasmakontsentratsioonid 21...26 μg/ml 250 mg / 250 mg annuse puhul; 21...55 μg/ml 500 mg / 500 mg annuse puhul ning 56...88 μg/ml 1000 mg / 1000 mg annuse puhul.
English: Poland: TIENAM
Estonian: Poola: TIENAM
English: Sodium bicarbonate
Estonian: Naatriumbikarbonaat
English: • Tremors and uncontrolled twitching of muscles
Estonian: • Treemorid ja tahtele allumatud lihastõmblused
English: Norway: Tienam
Estonian: Norra: Tienam
English: • common: affects 1 to 10 users in 100
Estonian: • Sage: esineb 1...10 kasutajal 100-st
English: Very rare cyanosis, tachycardia, palpitations
Estonian: Väga harv tsüanoos, tahhükardia, südamepekslemine
English: Bulgaria: Tienam
Estonian: Bulgaaria: Tienam
English: • A spinning sensation (vertigo), headache
Estonian: • Pöörlemistunne (peapööritus); peavalu
English: Dose adjustment is necessary for patients with impaired renal function (see section 4.2).
Estonian: Neerutalitluse häirega patsientidel on vaja annust kohaldada (vt lõik 4.2).
English: Nausea and vomiting appear to occur more frequently in patients with low number of white blood cells
Estonian: Iiveldus ja oksendamine esinevad sagedamini patsientidel,
English: • Blood disorders affecting the cell components of the blood and usually detected by blood tests
Estonian: • Harilikult vereanalüüsidega avastatavad vererakke kahjustavad verehaigused (sümptomiteks võivad olla kurnatus, naha kahvatus ja verevalumite püsimine vigastuste järel)
English: Czech Republic: Tienam
Estonian: Tšehhi: Tienam
English: • Inflammation of the colon with severe diarrhoea
Estonian: • Käärsoole põletik koos raske kõhulahtisusega
English: Frequency
Estonian: Esinemissagedus Näht
English: • Abnormal liver function detected by blood tests
Estonian: • Vereanalüüsides avalduvad maksatalitluse kõrvalekalded
English: • Seizures
Estonian: • Nõgestõbi
English: • Moraxalla catarrhalis 4: S ≤2 mg/l, R >2 mg/l
Estonian: • Moraxalla catarrhalis 4: T ≤ 2 mg/l, R > 2 mg/l
English: Belgium: Tienam
Estonian: Belgia: Tienam
English: Ear and labyrinth disorders
Estonian: Kõrva ja labürindi kahjustused Harv kuulmislangus
English: The lowered valproic acid levels can lead to inadequate seizure control; therefore, concomitant use of imipenem and valproic acid/sodium valproate is not recommended and alternative antibacterial or anti-convulsant therapies should be considered (see section 4.4).
Estonian: Seetõttu ei soovitata imipeneemi ja valproehapet/naatriumvalproaati samal ajal kasutada ning tuleb kaaluda teisi antibakteriaalseid või krambivastaseid ravimeid (vt lõik 4.4).
English: Cilastatin is a specific inhibitor of dehydropeptidase-I enzyme and effectively inhibits metabolism of imipenem so that concomitant administration of imipenem and cilastatin allows therapeutic antibacterial levels of imipenem to be attained in both urine and plasma.
Estonian: Tsilastatiin on ensüüm dehüdropeptidaas-I spetsiifiline inhibiitor, mis pärsib tõhusalt imipeneemi metabolismi.
English: • Streptococcus pneumoniae 4: S ≤2 mg/l, R >2 mg/l
Estonian: • Streptococcus pneumoniae 4: T ≤ 2 mg/l, R > 2 mg/l
English: • Haemophilus influenzae 4: S ≤2 mg/l, R >2 mg/l
Estonian: • Haemophilus influenzae 4: T ≤ 2 mg/l, R > 2 mg/l
English: Very rare polyarthralgia, thoracic spine pain
Estonian: Väga harv polüartralgia, lülisamba rinnaosa valu
English: Table 1: Reduced dose in adults with impaired renal function and body weight 70 kg*
Estonian: Tabel 1: Annuste vähendamine puuduliku neerutalitlusega täiskasvanul, kelle kehakaal on  70 kg* Kreatiniini kliirens (ml/min /1,73 m2)
English: Uncommon hypotension
Estonian: Aeg-ajalt hüpotensioon
English: Gram-positive anaerobes:
Estonian: Grampositiivsed anaerobsed bakterid:
English: It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant agent.
Estonian: Antibiootikumide kasutamisel koos suukaudsete antikoagulantidega on soovitatav INR' i mõõta sageli manustamise kestel ja varsti pärast seda.
English: GENERAL CLASSIFICATION FOR SUPPLY [To be completed nationally]
Estonian: RAVIMI VÄLJASTAMISTINGIMUSED [Täidetakse riiklikul tasandil]
English: 2: S ≤4 mg/l, R >8 mg/l
Estonian: 2: T ≤ 4 mg/l, R > 8 mg/l
English: system through which a lactate solution is being infused.
Estonian: TIENAMi võib siiski manustada läbi infusioonisüsteemi, mida kasutatakse laktaadilahuse infundeerimiseks.
English: • rare: affects 1 to 10 users in 10,000
Estonian: • Aeg-ajalt: esineb 1...10 kasutajal 1000-st
English: SPECIAL STORAGE CONDITIONS Do not store above 25C After reconstitution: Diluted solutions should be used immediately.
Estonian: Pärast lahustamist: Lahjendatud lahust tuleb kohe kasutada.
English: : S ≤4 mg/l, R >8 mg/l
Estonian: : T ≤ 4 mg/l, R > 8 mg/l
English: Urine concentrations of imipenem exceeded 10 g/ml for up to eight hours after a 500 mg/500 mg dose of TIENAM.
Estonian: Pärast TIENAMi 500 mg / 500 mg annuse manustamist ületas imipeneemi uriinikontsentratsioon 10 µg/ml kuni kaheksa tunni jooksul.
English: CNS adverse reactions such as myoclonic activity, confusional states, or seizures have been reported, especially when recommended doses based on renal function and body weight were exceeded.
Estonian: Peamiselt neerutalitluse ja kehakaalu põhjal soovitatud annuste ületamisega seonduvalt on kirjeldatud KNS-i kõrvaltoimeid, nt müokloonset aktiivsust, segasusseisundeid või krampe.
English: Gram-negative aerobes:
Estonian: Gramnegatiivsed aeroobsed bakterid:
English: • intra- and post-partum infections
Estonian: • sünnitusel ja sünnituse järel tekkivad infektsioonid
English: • Other streptococci 4: S ≤2 mg/l, R >2 mg/l
Estonian: • Teised streptokokid 4: T ≤ 2 mg/l, R > 2 mg/l
English: There is no dose adjustment necessary (see section
Estonian: Annuse kohaldamine ei ole vajalik (vt lõik 4.2).
English: TIENAM 500 mg/500 mg contains 37.6 mg of sodium (1.6 mEq) which should be taken into consideration by patients on a controlled sodium diet.
Estonian: Väikese naatriumisisaldusega dieedil olevate patsientide puhul peab võtma arvesse, et TIENAM 500 mg / 500 mg sisaldab 37,6 mg naatriumit (1,6 mEq).
English: Lithuania: TIENAM I.V.
Estonian: Küpros: Tienam I.V.
English: : S ≤2 mg/l, R >8 mg/l
Estonian: : T ≤ 2 mg/l, R > 8 mg/l
English: Common increases in serum transaminases, increases in serum alkaline phosphatase
Estonian: Sage transaminaaside ja aluselise fosfataasi sisalduse suurenemine seerumis